Results 11 to 20 of about 7,444 (141)
Cells, 2022 Patients with Parkinson’s disease (PD) exhibit distinct gut microbiota, which may promote gut-derived inflammation. Rifaximin is a nonabsorbable antibiotic that can modify gut microbiota.
Chien-Tai Hong +7 more
doaj +1 more source
The role of rifaximin in irritable bowel syndrome derived from a network meta-analysis of randomized control trials [PDF]
Microbiota in Health and Disease, 2020 Objective: Recent randomized control trials (RCTs), have demonstrated the beneficial therapeutic effects of rifaximin for the treatment of the irritable bowel syndrome (IBS).
T. Rokkas +8 more
doaj +1 more source
Rifaximin-Alpha and Other Crystalline Forms of Rifaximin: Are There Any Differences?
Антибиотики и Химиотерапия, 2020 Rifaximin is an antibiotic characterized by polymorphism. It has various crystalline forms with different pharmacological characteristics. Rifaximin acts locally in the digestive tract, therefore it is important for the absorption to be minimal and for ...
S. K. Zyryanov, E. A. Baybulatova
doaj +1 more source
Effect of rifaximin in the prevention of acute kidney injury and hepatorenal syndrome type II in Egyptian cirrhotic patients [PDF]
Zagazig University Medical Journal, 2021 Background: Hepatorenal syndrome type II and acute kidney injury found in 20% of cirrhotic patients. Rifaximin was found to reduce the frequency of hepatorenal syndrome type II and acute kidney injury in alcohol cirrhotic patients.
Ahmed El-Gebaly +2 more
doaj +1 more source
Dysbiosis in the small intestine: towards an optimal therapy to normalize the gut microbiota [PDF]
Microbiota in Health and Disease, 2021 Objectives: Rifaximin seems to be effective and safe in treating small intestinal bacterial overgrowth (SIBO), however, to date there is no consensus regarding the proper timing of therapy. The present study aims to provide preliminary data regarding the
G. Gasbarrini +4 more
doaj +1 more source
The Use of Rifaximin in Patients With Cirrhosis [PDF]
Hepatology, 2021 Rifaximin is an oral nonsystemic antibiotic with minimal gastrointestinal absorption and broad‐spectrum antibacterial activity covering both gram‐positive and gram‐negative organisms. Rifaximin is currently used worldwide in patients with cirrhosis for preventing recurrent HE because its efficacy and safety have been proven by large randomized clinical
Caraceni, Paolo +46 more
openaire +5 more sources
Journal of Global Antimicrobial Resistance, 2021 : Objectives: This study was designed to investigate the molecular epidemiology of Clostridioides difficile isolates in South Korea and to evaluate risk factors for rifaximin-non-susceptible C. difficile infection (CDI). Methods: A total of 413 patients
Dokyun Kim +5 more
doaj +1 more source
Frontiers in Pharmacology, 2021 Objective: Rifaximin has been approved for use as a first-line therapy for secondary prophylaxis of hepatic encephalopathy (HE). This article is to update existing evidence on efficacy and safety of rifaximin treatment and prevention for HE.Methods: We ...
Xianghui Han +8 more
doaj +1 more source
PLoS ONE, 2022 Rifaximin and lactulose are widely used in patients with hepatic encephalopathy (HE); however, data on whether the combined use of rifaximin and lactulose could yield additional benefits for patients with HE are limited and inconclusive.
Jian Fu, Yi Gao, Li Shi
doaj +2 more sources
Modulation of duodenal and jejunal microbiota by rifaximin in mice with CCl4-induced liver fibrosis
Gut Pathogens, 2023 Background Rifaximin is a poorly absorbed broad-spectrum antibiotic used for hepatic encephalopathy. Although increased Lactobacillaceae and decreased Bacteroidetes abundance are characteristic of hepatic encephalopathy, rifaximin does not dramatically ...
Kazuhiko Ikeuchi +7 more
doaj +1 more source